Back to top

Analyst Blog

Pacira Pharmaceuticals, Inc. (PCRX - Snapshot Report) released data supporting the use of Exparel infiltrated into the transversus abdominis plane (or iTAP) for postsurgical pain management.

Exparel is currently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce post-surgical analgesia. The drug was launched in Apr 2012.

A recent independent study evaluated 90 patients receiving laparoscopic bariatric surgery, of which 45 were treated with multimodal therapy including an Exparel iTAP. The study showed that patients who received Exparel experienced a 60.7% reduction in opioid consumption and a higher return of bowel function in 48 hours.

Additionally, phase IV study TRANSCEND was also conducted by Pacira, evaluating Exparel in patients undergoing gynecologic or colorectal surgery. Patients received either Exparel or normal saline iTAP as part of a multimodal pain regimen. This trial was discontinued and the company decided to analyze the data collected on the 67 patients recruited.

In this analysis, the total opioid rescue continued to show no signal, while the Overall Benefit of Analgesia Score (OBAS) demonstrated an advantage for Exparel compared to the group treated with normal saline.

In the first nine months of 2013, net Exparel revenues were $45.6 million. At the end of Sep 2013, Exparel had a customer base of 1,732. Pacira reported an average of 23 new customers per week in the third quarter.

Pacira currently carries a Zacks Rank #3 (Hold). Some better-ranked players in the pharma industry include Actelion Ltd. (ALIOF), Endocyte Inc. (ECYT - Snapshot Report) and Forest Laboratories Inc. . All the three stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GREEN PLAIN… GPRE 36.46 +3.79%
MATRIX SERV… MTRX 30.90 +2.93%
ENZO BIOCHE… ENZ 5.20 +2.77%
VIPSHOP HOL… VIPS 191.34 +2.23%
SUPER MICRO… SMCI 25.08 +2.08%